<DOC>
	<DOCNO>NCT01620840</DOCNO>
	<brief_summary>Lacosamide new antiepileptic drug ( AED ) market Vimpat three different formulation , tablet , oral syrup solution intravenous infusion . Lacosamide approve adjunctive therapy epilepsy patient partial onset seizure without secondary generalization . The i.v . solution use patient oral administration possible adequate . Bioequivalence oral tablet safety could demonstrate healthy volunteer patient switch tablet Lacosamide i.v . solution . A recently publish study demonstrate feasibility single loading dose 300 mg . The aim Lacosamide i.v . registry collect systematically data safety , tolerability administration procedure Lacosmide i.v . use routine daily clinical practice , mainly hospital . These data help treat physician optimize use Lacosamide i.v . clinical routine .</brief_summary>
	<brief_title>Lacosamid-i.v.-Register</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>data collect patient registry ehtical committee must notify registry write data consent must properly execute document</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>oral administration Lacosamide possible adequate</keyword>
</DOC>